Lone Star Funds’ $3bn deal for Lonza’s CHI division
Listed Swiss life sciences company Lonza Group has reached a definitive agreement to sell a sixty percent stake in its Capsules and Health Ingredients (CHI) division to private equity firm Lone Star Funds. The transaction values the unit at an enterprise value of 2.3bn Swiss francs, or approximately $3bn, representing an 8.5x enterprise value to EBITDA multiple on 2025 results.…